Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Phillips Wealth Planners LLC

Phillips Wealth Planners LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the third quarter, Holdings Channel reports. The institutional investor owned 4,682 shares of the biopharmaceutical company’s stock after acquiring an additional 193 shares during the quarter. Phillips Wealth Planners LLC’s holdings in Gilead Sciences were worth $406,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Manning & Napier Advisors LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth about $25,328,000. Legal & General Group Plc raised its position in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Gilead Sciences in the first quarter worth $462,000. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after buying an additional 33,162 shares during the period. Finally, Cetera Investment Advisers boosted its stake in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after purchasing an additional 119,909 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.8 %

Gilead Sciences stock opened at $89.51 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $89.74. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $111.44 billion, a PE ratio of 109.16, a PEG ratio of 3.07 and a beta of 0.18. The firm’s fifty day moving average is $83.79 and its 200 day moving average is $74.12.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock worth $3,033,340 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $100.00 in a research report on Monday, October 7th. Barclays upped their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, BMO Capital Markets boosted their target price on Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Ten analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $86.85.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.